Log In
Print
BCIQ
Print
Print this Print this
 

Pralatrexate

  Manage Alerts
Collapse Summary General Information
Company Oxford Regulatory Solutions Ltd.
DescriptionSmall molecule dihydrofolate reductase (DHFR) inhibitor
Molecular Target Dihydrofolate reductase (DHFR)
Mechanism of ActionDihydrofolate reductase (DHFR) inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentDiscovery
Standard IndicationT cell lymphoma
Indication DetailsTreat cutaneous T cell lymphoma (CTCL); Treat peripheral T cell lymphoma (PTCL); Treat relapsed or refractory peripheral T cell lymphoma (PTCL)
Regulatory Designation

U.S. - Orphan Drug (Treat relapsed or refractory peripheral T cell lymphoma (PTCL));
EU - Orphan Drug (Treat relapsed or refractory peripheral T cell lymphoma (PTCL));
EU - Orphan Drug (Treat cutaneous T cell lymphoma (CTCL))

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today